Acinetobacter baumannii is a common cause of serious nosocomial infections. Although
community-acquired infections are observed, the vast majority occur in people with …

This review deeply addresses for the first time the diversity, regulation and mechanisms
leading to mutational overexpression of intrinsic β-lactamases from non-fermenting and …

Clostridium difficile is the causative agent of the deadly C. difficile infection. Resistance of
the pathogen to β-lactam antibiotics plays a major role in the development of the disease …

Objectives Cefiderocol (CFDC), a siderophore cephalosporin, is active against Gram-
negative bacteria including carbapenem-resistant Acinetobacter baumannii (CRAB). In this …

Objectives To measure the variability in carbapenem susceptibility conferred by different
OxaAb variants, characterize the molecular evolution of oxaAb and elucidate the …

OXA‐51 is a class D β‐lactamase that is thought to be the native carbapenemase of
Acinetobacter baumannii. Many variants of OXA‐51 containing active site substitutions have …

Successful treatment of Acinetobacter baumannii infections require early and appropriate
antimicrobial therapy. One of the first steps in this process is understanding which β …

OXA-66 is a member of the OXA-51 subfamily of class D β-lactamases native to the
Acinetobacter genus that includes Acinetobacter baumannii, one of the ESKAPE pathogens …

OXA-239 is a class D carbapenemase isolated from an Acinetobacter baumannii strain
found in Mexico. This enzyme is a variant of OXA-23 with three amino acid substitutions in or …

Carbapenems—one of the important last-line antibiotics for the treatment of gram-negative
infections—are becoming ineffective for treating Acinetobacter baumannii infections. Studies …